

E
iii) a plasma protein selected from the group consisting of serum albumin, gamma globulin, wherein the plasma protein is non-covalently bound to the therapeutically active drug;

prepared by the process comprising the steps of:

- a) dissolving the therapeutically active drug in a water-miscible, pharmaceutically acceptable organic solvent;
 - b) combining the solution with an aqueous solution of plasma protein; and
 - c) removing the organic solvent;--
-

REMARKS

Claims 30-37, 42-90, and 93-94 have been canceled without prejudice. New claim 95 is added as suggested by the examiners during the interview. No new matter is introduced and the support for the new claim can be found throughout the specification.

As suggested by the examiners, claim 95 is introduced as a product-by-process claim. The claim 95 recites exemplified active substances and plasma protein. Thus, the exemplified therapeutic active drug includes paclitaxel (examples II.1-5 and examples III. 5 and IV.2), amphotericin B (examples II.24-25 and examples II. 25, and III. 1), camptothecin (examples II-26-27 and example III. 2), carbamazepin (example II. 29, and example III. 3), cyclosporine A (examples II. 30-32, example III. 4), and propofol (examples II. 33-34 and example III. 6).

Applicants believe that the present claim is free of prior art and patentable. The scope of the new claim is proper and fully supported by the disclosure. In view of the foregoing, allowance of claim 95 is respectfully requested. The examiner is invited to contact applicants undersigned attorney at (212) 908-6018 concerning this amendment.

Respectfully submitted,

Date: January 21, 2003

By


Siu K. Lo

Reg. No. 46,877

Kenyon & Kenyon
One Broadway
New York, NY 10004
(212) 908-6018